Similarly, clinical data from 86 cases of high-grade EOC were analyzed, and it was discovered that the absence of PARP1 expression as determined by immunohistochemistry predicted superior PFS and chemotherapy sensitivity in patients with ovarian cancer treated with adjuvant platinum-based chemotherapy (30). This evidence concerns the gene PARP1 and ovarian carcinoma.